Bicara Therapeutics said enrollment is advancing in its pivotal FORTIFI-HN01 trial in HPV-negative head and neck cancer, with interim topline data expected in m

Bicara Therapeutics said enrollment is advancing in its pivotal FORTIFI-HN01 trial in HPV-negative head and neck cancer, with interim topline data expected in mid-2027. The Q3 update also follows the earlier launch of the FORTIFI-FLEX study.